http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
조시진,권수경,Jung Da Mi,박순철,김향경,김장용,윤상섭 대한외과초음파학회 2019 대한외과초음파학회지 Vol.6 No.2
Purpose: Endovascular aneurysm repair (EVAR) is a minimally invasive alternative to open repair for patients with abdominal aortic aneurysm (AAA). Yet the follow-up after EVAR with lifelong post-interventional imaging is mandatory in order to detect complications such as endoleaks or stent migration. Computed tomography angiography (CTA) is considered the standard imaging modality and widely used for follow-up, although patients are exposed to both radiation and nephrotoxic contrast medium. The aim of this study was to determine the diagnostic efficacy of contrast-enhanced ultrasound (CEUS) for detecting post EVAR endoleaks compared with that of CTA, which is considered as the gold standard. Methods: From January 2010 to August 2019, 27 patients who underwent CEUS and CTA for follow-up after elective EVAR at a single center were retrospectively analyzed. The presence of endoleak was compared between CTA and CEUS. Results: The 27 paired CTA and CEUS studies were analyzed. Eleven patients had endoleak detected on CEUS and they had the same findings with CTA. One patient had endoleak detected on CEUS, but this was not detected on CTA. Three patients didn’t have endoleak detected on CEUS, but endoleak was detected on CTA. 13 patients had no endoleak detected on CEUS or CTA. Assuming CTA is the gold standard, the sensitivity and specificity of CEUS to detect endoleak were 92.3%, and 78.6% respectively. Conclusion: CEUS can be used as a viable and feasible imaging alternative for the follow-up and the detection of endoleak after EVAR with the additional benefit of being a real-time non-ionizing radiation examination.
강영준,백종민,김용석,전예원,YOO TAE KYUNG R,유지영,신창현,조시진,최훈,오세정 한국유방암학회 2021 Journal of breast cancer Vol.24 No.6
Purpose: The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted the rates of screening, case identification, and referral for cancer diagnosis. We investigated the diagnosis and surgery status of breast cancer before and after the COVID-19 pandemic at a multi-institutional level. Methods: We collected breast cancer data from the clinical data warehouse which contained the medical records of patients from six academic institutions in South Korea. Patients were divided into two groups: February to April (period A) and May to July (period B). The data from the two groups were then compared against the same periods in 2019 and 2020. The primary objective was to investigate the differences in breast cancer stages before and after the COVID-19 pandemic. Results: Among 3,038 patients, there was a 9.9% reduction in the number of diagnoses in 2020. This decrease was more significant during period A than period B. The breast cancer stage was not statistically different in period A (p = 0.115), but it was in period B (p = 0.001). In the subset analysis according to age, there was a statistical difference between 2019 and 2020 in period B for patients under the age of 65 years (p = 0.002), but no difference was observed in the other groups. Conclusion: The number of breast cancer cases declined during the pandemic, and the staging distribution has changed after the pandemic peak.